Agilent Technologies, Inc. news

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Jeffrey Gordon has received an Agilent Thought Leader Award in support of his pioneering research into the mutually beneficial relationship between the human body and the tens of trillions of microbes that inhabit the gastrointestinal tract.

Dr. Gordon directs the Center for Genome Sciences and Systems Biology at Washington University School of Medicine in St. Louis. The award, which includes funding and c

Agilent Technologies Inc. (NYSE: A) today named Dr. Mitchell Guttman the winner of its 2015 Early Career Professor Award. The award, now in its seventh year, recognizes one early career professor for his or her exceptional, original research contributions and outstanding potential for future research. Dr. Guttman was selected from a global pool of professors contributing to the understanding and use of RNA-based technologies for genome editing and control.

Dr. Guttman is assistant pro

Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine.

Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge research in all aspects of redox biology. Seahorse was acquired by Agilent Technologies on Nov.

Agilent Technologies Inc. (NYSE: A) today introduced the 4200 TapeStation system, a fully automated instrument that enables scientists to rapidly analyze up to 96 DNA samples at a time.

"We designed the new instrument —the successor to our popular 2200 TapeStation system—to address the need for both higher throughput and higher quality in next-generation sequencing labs," said Knut Wintergerst, Marketing and Support manager for Agilent`s microfluidics product line.

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC.

Dako developed the diagnostic, known as PD-L1 IHC 28-8 pharmDx, through a collaboration with